Clinical Trial Search

Primary: Individual Peak Booster Rate by ELISA (Percentage of Participants) — 100.0; 100.0 percentage of subjects

Primary: Number of Participants With Postoperative Healthcare Acquired Infections — 108; 116 Participants

Primary: Percentage of Active Members Who Have at Least One Post in Group Chat Session. — 32 Participants

Primary: Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase — 1; 0; 2; 0 Participants

Primary: Number of Patients Treated and Re-treated Based on Presence/Absence of Active Leakage — 3; 0; 61; 121 Patients — p=<0.0001

Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants

Primary: Change in Rate of Use — 85; 28 Participants — p=0.01

Primary: Number of Participants With a Favorable Clinical Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 177; 187; 7; 7…

Primary: Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf) — 1199; 1908; 2075; 1895 ng•hr/mL

Primary: Physical Activity (Reporting Change in Physical Activity From Baseline to Six-week Follow-up) — 21.6 minutes/day

Primary: Change in Levator Hiatus Area at Rest Measured Via 3-dimensional Ultrasound at Gestational Week 21 and 37. — 2.0 cm

Primary: Percentage of Participants Who Achieved Seizure Free Interval of At Least 30 Minutes After Initial Dose (Dose 1) of Study Drug — 48.0 percentage of participants

Primary: Part 1: Number of Participants Experiencing a Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants

Primary: Mucosal Recession Change — 0.1; 0.1 milimeters